Abstract
The active immunotherapy was performed on the 9 patients who had had pulmonary resections for the carcinoma. Membrane extracts of the autochthonous tumor cell were used for a tumor antigen and AD6 fraction used for an adjuvant. This AD6 fractionated from acetylating Wax D has been proved as having only adjuvant activity and not having antigenicity.
Following the resection of the lung cancer the tumor cell vaccine was once or twice innoculated subcutaneously in the upper extremity.
The survival rate of 9 cases treated with an active immunotherapy increased rather higher up to 18 months, as compared to the other 218 cases without an immunotherapy. The 3 year survival rate, however, decreased down to the survival rate of 218 cases.
According to our studies, the active immunotherapy seemed to be effective in the prolongation of lifespan during the first 18 months. A disadvantage of this therapy was hard-healing ulcer at the injection site.
